Beam Therapeutics BEAM External Research And Development Expenses — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's external research and development expenses — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's external research and development expenses — research and development expense?
- Beam Therapeutics (BEAM) reported external research and development expenses — research and development expense of $30.08M in Q1 2026.
- How has Beam Therapeutics's external research and development expenses — research and development expense changed year-over-year?
- Beam Therapeutics's external research and development expenses — research and development expense decreased by 12.6% year-over-year, from $34.42M to $30.08M.
- What is the long-term trend for Beam Therapeutics's external research and development expenses — research and development expense?
- Over 3 years (2022 to 2025), Beam Therapeutics's external research and development expenses — research and development expense has grown at a 8.3% compound annual growth rate (CAGR), from $112.38M to $142.69M.
- What does external research and development expenses — research and development expense mean?
- This metric represents the total costs incurred by the company specifically attributed to external research and development activities, such as outsourced clinical trials, contract research organizations, and external laboratory services. It reflects the company's reliance on third-party partners to advance its genetic medicine pipeline and therapeutic programs. Monitoring this expense helps investors understand the company's capital allocation toward external innovation versus internal research capabilities.